Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint
Raffaella Ravinetto,
Anja De Weggheleire,
Thomas P. C. Dorlo,
Sven Francque,
An Sokkab,
Corinne Pouget,
Bruno Meessen,
Patricia Tabernero,
Paul N. Newton,
Lut Lynen